Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 19/20 | 0.80 |
| ▸ | PPIB | P23284 | 6/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | PPIF | P30405 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.61 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530854 | 0.96 | PPIA (0.87) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL18737378 | 0.95 | PPIA (0.86) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL18737005 | 0.92 | PPIA (0.81) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183864 | 0.91 | PPIA (0.94) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL18530860 | 0.90 | PPIA (0.77) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL19861467 | 0.90 | PPIA (0.78) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183092 | 0.89 | PPIA (0.78) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| Scy 635 SCHEMBL15183872 | 0.88 | PPIA (1.00) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| Scy 635 SCHEMBL15183874 | 0.88 | PPIA (1.00) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| Scy 635 SCHEMBL21765630 | 0.88 | PPIA (1.00) | PPIAPPIBCYP3A4CYP2C9PPIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | PPIA 610/4885PPIB 297/4885CYP3A4 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.